Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $1,039,720.00 in Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 44,000 shares of the company’s stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,627,468.99. The trade was a 38.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Gary Ingenito also recently made the following trade(s):

• On Tuesday, May 13th, Gary Ingenito sold 200,000 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00.
• On Wednesday, March 5th, Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $22.09, for a total value of $991,929.36.

Catalyst Pharmaceuticals Trading Up 2.5%

Catalyst Pharmaceuticals stock opened at $24.37 on Friday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.75 and a 12 month high of $26.16. The stock’s 50 day moving average is $23.23 and its 200-day moving average is $22.47. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of 20.65, a PEG ratio of 3.31 and a beta of 0.70.

Analyst Ratings Changes

Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Finally, Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $32.29.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CPRX. Barclays PLC grew its position in shares of Catalyst Pharmaceuticals by 129.4% in the third quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock valued at $4,939,000 after purchasing an additional 140,129 shares during the last quarter. Franklin Resources Inc. grew its position in Catalyst Pharmaceuticals by 3.4% during the third quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company’s stock worth $1,221,000 after buying an additional 1,967 shares in the last quarter. JPMorgan Chase & Co. grew its position in Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock worth $8,116,000 after buying an additional 33,888 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Catalyst Pharmaceuticals during the fourth quarter worth approximately $134,000. Finally, Richard P Slaughter Associates Inc grew its position in Catalyst Pharmaceuticals by 1.9% during the fourth quarter. Richard P Slaughter Associates Inc now owns 149,406 shares of the biopharmaceutical company’s stock worth $3,118,000 after buying an additional 2,770 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.